Table 1 Characteristics of patients in phase 1 and phase 2

N

44

50

Age (years)

63.3 ± 14.1

68.6 ± 12.2

0.06

Sex (male/female)

40/4

35/15

0.01

Etiology

23 DCM

31 DCM

0.34

21 ICM

19 ICM

Number of patients with scar on CMR n(%)

24 (55)

21 (42)

0.22

Scar burden on CMR in those patients with scar (% of myocardium)

21.4 ± 7.9

24.4 ± 11.4

0.35

QRS duration (ms)

154 ± 24

146 ± 21

0.11

QRS morphology (LBBB/RBBB/IVCD)

31/5/8

28/4/18

0.15

Rhythm

38 SR

42 SR

0.53

6 AF

8 AF

Beta blockers n(%)

40 (91)

38 (76)

0.11

ACEI/ARB n(%)

43 (98)

49 (98)

0.84

Diuretics n(%)

27 (62)

35 (70)

0.44

Aldosterone antagonists n(%)

17 (38)

33 (66)

0.27

NYHA class n(%)

II

7 (16)

12 (24)

0.23

III

35 (80)

38 (76)

IV

2 (4)

0

QOL score pre CRT

51 ± 24

50 ± 26

0.41

6 minute walk distance (m)

255 ± 112

295 ± 149

0.02

Ejection fraction (%)*

25 ± 9

22 ± 9

0.14

End diastolic volume (ml)*

232 ± 72

218 ± 90

0.43

End systolic volume (ml)*

175 ± 67

172 ± 82

0.88

LV lead position

0.86

Lateral

20

21

Posterolateral

21

22

Anterior

3

5

Posterior

3

2

LV lead in area with >50% transmural scar n(%)

4(9)

7(14)

0.46